

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following statements best characterizes the progression-free survival outcomes with first-line trastuzumab deruxtecan (T-DXd) and pertuzumab in comparison to paclitaxel/trastuzumab/pertuzumab (THP) for patients with advanced HER2-positive breast cancer in a subgroup analysis of the Phase III DESTINY-Breast09 trial?
 - a. T-DXd and pertuzumab demonstrated a benefit for only those patients with hormone receptor (HR)-negative status
 - b. T-DXd and pertuzumab did not demonstrate a benefit for patients with PI3KCA mutations
 - c. T-DXd and pertuzumab demonstrated a benefit regardless of HR or PI3KCA mutation status
2. What was the relative reduction in the risk of invasive disease recurrence with T-DXd according to results from the Phase III DESTINY-Breast05 study?
 - a. Less than 10%
 - b. Between 15% and 25%
 - c. Between 30% and 40%
 - d. Greater than 50%
3. Recently presented data from the Phase III DESTINY-Breast11 study comparing T-DXd followed by THP before surgery to standard neoadjuvant therapy for high-risk HER2-positive localized breast cancer reported which efficacy outcome?
 - a. A numerical but nonsignificant improvement in pathologic complete response (pCR) with T-DXd followed by THP
 - b. A statistically significant improvement in pCR with T-DXd followed by THP
 - c. A numerical but nonsignificant improvement in overall survival (OS) with T-DXd followed by THP
 - d. A statistically significant improvement in OS with T-DXd followed by THP
4. In the Phase III DESTINY-Breast05 study, which of the following adverse events was much more commonly associated with T-DXd therapy than with T-DM1?
 - a. Arthralgia
 - b. Nausea
 - c. Headache
 - d. Thrombocytopenia
5. What was the reported hazard ratio for event-free survival in the Phase III DESTINY-Breast11 study comparing T-DXd followed by THP before surgery to standard neoadjuvant therapy for high-risk HER2-positive localized breast cancer?
 - a. 0.15
 - b. 0.32
 - c. 0.56
 - d. 0.81